Back to first-pass browser

First-pass extracted concept

viral and non-viral vectors

Candidate: concept label3 source documents6 linked claims
Jump to explainersJump to evidenceJump to sourcesJump to claims
Live refresh every 5sNext refresh in 5s

Extracted Explainers

What the tool is doing

The review describes viral and non-viral vectors as delivery modalities used in preclinical AF gene-therapy studies.

Source 1DOIPubMed

The abstract states that the therapeutic landscape is expanded through the use of viral and non-viral vectors. They are presented as delivery classes rather than specific named tools.

Source 2DOIPubMed

Resources required

Use requires a gene-delivery vector platform suitable for cardiac or atrial application, but the abstract does not specify exact platforms or components.

Source 1DOIPubMed

What problem it solves

These vectors are used to modulate molecular drivers of AF.

Source 1DOIPubMed

What it does not solve

The abstract states that current AF gene therapies still face translational barriers and none has FDA approval.

Source 1DOIPubMed

Alternatives

The abstract contrasts gene therapy with existing AF treatments including drugs and catheter ablation.

Source 1DOIPubMed

Evidence Snippets

This review summarizes recent preclinical studies using viral and non-viral vectors
Evidence 1Source 1DOIPubMedprovenance
significantly expanding the therapeutic landscape using viral and non-viral vectors
Evidence 2Source 2DOIPubMedprovenance
In this review, we will discuss the most commonly used tools for the delivery of genetic material in the CNS, including viral and non-viral vectors; their main applications; their advantages and disadvantages.
Evidence 3Source 3DOIPubMedprovenance

Supporting Sources

Linked Claims

Claim 1delivery scopesupports2025Source 2DOIPubMed

The therapeutic landscape described in the source uses viral and non-viral vectors.

Quoted textsource-backed
using viral and non-viral vectors
Claim 2limitationsupports2025Source 1DOIPubMed

Challenges in atrial targeting, immune control, and durable expression are barriers to atrial fibrillation gene-therapy translation.

Claim 3scope summarysupports2025Source 1DOIPubMed

Recent preclinical atrial fibrillation gene-therapy studies include viral vectors, non-viral vectors, atrial-specific delivery strategies, and targets involving ion channels, fibrosis, and oxidative stress.

Claim 4therapeutic rationalesupports2025Source 1DOIPubMed

Gene therapy is a promising approach to modulate molecular drivers of atrial fibrillation.

Claim 5translational statussupports2025Source 1DOIPubMed

No atrial fibrillation gene therapy has FDA approval.

Claim 6review summarysupports2019Source 3DOIPubMed

Gene therapy is presented as an attractive option for CNS disorders because it enables delivery of genetic material encoding therapeutic molecules.